Calyxt

01 / WHAT IT BUILT

What the company did

Calyxt was a plant-based synthetic biology company founded in 2010 as a spinout of Cellectis. It used TALEN gene-editing technology — molecular scissors that create desirable traits without adding foreign DNA — to develop crop products including Calyno, a high-oleic, zero-trans-fat soybean oil; high-fiber wheat; improved alfalfa; hemp; and winter oats. The company went public on Nasdaq (CLXT) in 2017 and sold traits and seeds through licensing and partnerships across the agricultural supply chain.

03 / EVENT HISTORY

Events in the structured record

1. 2010
   Founded

   Founded as a Cellectis spinout in New Brighton, Minnesota, to commercialize TALEN plant gene-editing technology developed at the University of Minnesota.

2. 2017
   IPO

   Went public on Nasdaq under ticker CLXT, raising roughly $100 million to develop and commercialize gene-edited crop traits.

3. 2019
   Product launches

   Launched Calyno high-oleic soybean oil commercially and expanded its trait pipeline into wheat, alfalfa, hemp and oats through licensing and co-development partnerships.

4. 2023
   Merger with Cibus

   Stockholders approved a merger with Cibus Global in an all-stock transaction. The deal closed on May 31, 2023; the combined company was renamed Cibus, Inc., traded on Nasdaq under ticker CBUS and was led by Cibus management, with Calyxt shareholders owning about 5% of the combined company.